fingolimod hydrochloride has been researched along with EBV Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, G; Hopkins, RS; Kim, E; Okada, CY; White, KP; Wills, A | 1 |
| Adinolfi, LE; Alfieri, G; Dalla Mora, L; Lus, G; Marrone, A; Rainone, I; Rinaldi, L; Signoriello, E | 1 |
2 other study(ies) available for fingolimod hydrochloride and EBV Infections
| Article | Year |
|---|---|
Primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma (DLBCL) in a patient taking fingolimod.
Topics: Biopsy; Epstein-Barr Virus Infections; Fingolimod Hydrochloride; Herpesvirus 4, Human; Humans; In Situ Hybridization; Lymphocytes; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; RNA, Viral; Skin; Skin Diseases, Viral; Sphingosine 1 Phosphate Receptor Modulators | 2019 |
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment.
Topics: Adult; Cholagogues and Choleretics; Epstein-Barr Virus Infections; Fingolimod Hydrochloride; Herpesvirus 4, Human; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Male; Multiple Sclerosis; Recurrence; Treatment Outcome; Ursodeoxycholic Acid; Withholding Treatment | 2014 |